Biomedical Implications and Birth of a
Market
NEEDHAM, MA, UNITED STATES - Jun 19, 2015 - Insight Pharma Reports releases the
report, The Human Microbiome: Biomedical Implications and Birth of
a Market, which covers the evolution of microbiome research
and its growth in the commercial market. Specific areas of study
include microbial ecology, systems biology, diet, diagnostics,
contributions in health and disease, and infectious
disease.
This report focuses on biomedical aspects of human microbiome
research, development, and commerce. It covers necessary background
material, evolution of the field, progress in basic research,
activities in the developing commercial market, deal activity,
interviews with experts, and trends in microbiome research and
commerce. Information for the report has been drawn from the
scientific literature, discussions with knowledgeable individuals,
and an online survey of people working in this area.
Organizations covered in this report include: Companies
covered in this space include: 4D Pharma, ActoGenixAOBiome,
AvidBiotics, CIPAC Limited, Enterome Bioscience, Human Longevity,
Metabiomics, Microbiome Therapeutics, Miomics, OmniBiome
Therapeutics, OptiBiotix, Osel Inc., OxThera, PathoGenetix,
Rebiotix, Ritter Pharmaceuticals, Second Genome, Seres Health,
uBiome, UCB, UC San Francisco, Vedanta, ViThera Pharmaceuticals,
and Whole Biome.
Exclusive interview transcripts with the following experts
include:
- Peter DiLaura, President & CEO, Second Genome
- Colleen Cutcliffe, CEO, Whole Biome
- James Brown, PhD; Head, Computational Biology; Head, Microbiome
Matrix Team; GlaxoSmithKline
- Jack Gilbert, PhD., Environmental Microbiologist, Assoc. Prof.,
Department of Ecology & Evolution, Argonne National
Laboratory
- Glenn Tillotson, PhD, Senior Partner, Transcrip Partners,
USA
- Peter P. Lee, MD, Executive Chairman, Osel, Inc.
- Gregory Kuehn, VP Business Development and Marketing,
Metabiomics
- Stephen Elms, CEO, Miomics Bio-Therapeutics
- Sydney M. Finegold, M.D., Emeritus Professor of Medicine, and
Emeritus Professor of Microbiology, Immunology, and Molecular
Biology, UCLA School of Medicine; Staff Physician, Infectious
Disease Section, VA Greater Los Angeles Healthcare System
For more information on this report, visit
http://www.insightpharmareports.com/human-microbiome-report
About Insight Pharma Reports (http://www.InsightPharmaReports.com)
Insight Pharma Reports are written by experts in consulting and
industry who collaborate with us to provide a series of reports
that evaluate the salient issues in pharmaceutical technology,
business, and therapy markets. Insight Pharma Reports are used by
leading pharmaceutical, biotech, diagnostic, consulting, and
financial companies to keep abreast of the latest advances in
pharmaceutical R&D, their potential applications and business
impacts, and their current and future position in the marketplace.
Insight Pharma Reports is a division within Cambridge Healthtech
Institute.